Combination treatment with anti-TNFα and nonbiologic disease-modifying antirheumatic drugs (DMARDs) resulted in the significant up-regulation of miR-16-5p, miR-23-3p, miR125b-5p, miR-126-3p, miRN-146a-5p and miR-223-3p in RA patients [110]. This evidence concerns the gene TNF and rheumatoid arthritis.